HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

scientific article published on 20 November 2010

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.PRP.2010.08.005
P698PubMed publication ID21095069

P50authorYi-Long WuQ42663698
P2093author name stringLi Li
Meng Yao
Ning Liao
Guo-chun Zhang
Yan-hui Liu
Fang-ping Xu
Xue-rui Li
P433issue1
P921main subjectductal carcinomaQ5311598
P304page(s)1-7
P577publication date2010-11-20
P1433published inPathology, Research and PracticeQ15758752
P1476titleHER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component
P478volume207

Reverse relations

cites work (P2860)
Q35735366Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer
Q36897778Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer
Q38648122Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ
Q51145791Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Q38250760Ductal carcinoma in situ with distorting sclerosis on core biopsy may be predictive of upstaging on excision
Q38429498Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer
Q39218576Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression
Q49061414Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.
Q46057336Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast
Q36449263Potential use of vaccines in the primary prevention of breast cancer in high-risk patients
Q54513997Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
Q52920490Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management.
Q50592584Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Q40588935Sonographic Features of Ductal Carcinoma In Situ of the Breast With Microinvasion: Correlation With Clinicopathologic Findings and Biomarkers
Q35660389The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
Q35201328The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease
Q90394997Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile